1L CT (HR+HER2-): Active treatments
•
In patients with taxane-naive and anthracycline-resistant MBC or with anthracycline
maximum cumulative dose or toxicity (i.e. cardiac) who are being considered for
further CT, taxane-based therapy, preferably as single agents, would usually be
considered as treatment of choice.
–
Other options are, available and effective, such as capecitabine and vinorelbine, particularly if
avoiding alopecia is a priority for the patient
•
If given in the adjuvant setting, a taxane can be re-used as 1st line therapy,
particularly if there has been at least 1 year of DFS
[ESMO 2016]
Previous Antras (Taxane naïve or not)
Anthras re-challenge (liposomal)
Taxanes (or taxane re-challenge)
Capecitabine or Vinorelbine
Cardoso et al Ann Oncol 2016;
